GlassScriptPhysician profile
Robin J Miller
NPI 1932234317
$1,242.38
in general payments reported to CMS, 2019-2025
9 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $176 · 2022: $120 · 2023: $220 · 2024: $125 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $263.48 | 2019-2022 | |
| Novo Nordisk INC | $259.05 | 2019-2020 | |
| Depuy Synthes Sales INC. | $176.18 | 2019-2020 | |
| Madrigal Pharmaceuticals | $142.17 | 2025 | Rezdiffra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2024 | Caplyta |
| Intra-Sana Laboratories | $114.49 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Boston Scientific Corporation | $105.73 | 2023 | Ranger |
| Novartis Pharmaceuticals Corporation | $42.01 | 2019 | |
| Glaxosmithkline, LLC. | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.